| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 78 | 2025 | 162 | 22.840 |
Why?
|
| Angiogenesis Inhibitors | 103 | 2025 | 219 | 19.280 |
Why?
|
| Macular Edema | 57 | 2025 | 92 | 15.760 |
Why?
|
| Visual Acuity | 111 | 2025 | 705 | 14.690 |
Why?
|
| Wet Macular Degeneration | 36 | 2025 | 44 | 10.810 |
Why?
|
| Macular Degeneration | 33 | 2025 | 127 | 10.450 |
Why?
|
| Ranibizumab | 61 | 2025 | 75 | 10.430 |
Why?
|
| Vascular Endothelial Growth Factor A | 89 | 2025 | 446 | 10.000 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 51 | 2024 | 102 | 9.420 |
Why?
|
| Intravitreal Injections | 101 | 2025 | 148 | 9.390 |
Why?
|
| Tomography, Optical Coherence | 91 | 2025 | 561 | 8.830 |
Why?
|
| Recombinant Fusion Proteins | 52 | 2025 | 801 | 8.670 |
Why?
|
| Fluorescein Angiography | 69 | 2025 | 152 | 7.580 |
Why?
|
| Geographic Atrophy | 17 | 2025 | 24 | 7.490 |
Why?
|
| Macula Lutea | 19 | 2025 | 48 | 5.310 |
Why?
|
| Retinal Diseases | 18 | 2024 | 180 | 4.880 |
Why?
|
| Retinal Detachment | 16 | 2025 | 79 | 4.820 |
Why?
|
| Diabetes Mellitus | 19 | 2024 | 930 | 4.660 |
Why?
|
| Vitrectomy | 26 | 2025 | 91 | 4.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2024 | 551 | 4.390 |
Why?
|
| Retinal Vein Occlusion | 17 | 2022 | 27 | 4.340 |
Why?
|
| Retinal Vessels | 24 | 2024 | 78 | 4.330 |
Why?
|
| Choroidal Neovascularization | 12 | 2023 | 34 | 4.220 |
Why?
|
| Retinal Perforations | 10 | 2024 | 25 | 3.670 |
Why?
|
| Laser Coagulation | 17 | 2023 | 128 | 3.530 |
Why?
|
| Bevacizumab | 20 | 2024 | 79 | 2.910 |
Why?
|
| Retina | 22 | 2023 | 499 | 2.510 |
Why?
|
| Choroid | 9 | 2025 | 41 | 2.320 |
Why?
|
| Humans | 250 | 2025 | 133390 | 2.170 |
Why?
|
| Aged | 98 | 2025 | 21605 | 2.150 |
Why?
|
| Scleral Buckling | 9 | 2022 | 14 | 2.120 |
Why?
|
| Glucocorticoids | 10 | 2024 | 401 | 2.030 |
Why?
|
| Endophthalmitis | 7 | 2016 | 69 | 2.020 |
Why?
|
| Middle Aged | 105 | 2025 | 29208 | 2.020 |
Why?
|
| Follow-Up Studies | 43 | 2025 | 5455 | 1.940 |
Why?
|
| Aged, 80 and over | 49 | 2025 | 7159 | 1.790 |
Why?
|
| Fundus Oculi | 21 | 2025 | 67 | 1.750 |
Why?
|
| Prospective Studies | 48 | 2025 | 6570 | 1.700 |
Why?
|
| Male | 124 | 2025 | 65685 | 1.630 |
Why?
|
| Photography | 6 | 2022 | 88 | 1.620 |
Why?
|
| Treatment Outcome | 58 | 2025 | 12971 | 1.610 |
Why?
|
| Female | 129 | 2025 | 71455 | 1.570 |
Why?
|
| Peptides, Cyclic | 2 | 2023 | 57 | 1.540 |
Why?
|
| Ischemia | 10 | 2021 | 383 | 1.470 |
Why?
|
| Retinal Pigment Epithelium | 6 | 2025 | 38 | 1.340 |
Why?
|
| Retrospective Studies | 59 | 2025 | 17378 | 1.330 |
Why?
|
| Vitreous Detachment | 3 | 2024 | 11 | 1.320 |
Why?
|
| Complement Inactivating Agents | 4 | 2023 | 12 | 1.310 |
Why?
|
| Complement C3 | 4 | 2023 | 54 | 1.250 |
Why?
|
| Fovea Centralis | 4 | 2020 | 10 | 1.160 |
Why?
|
| Endothelial Growth Factors | 12 | 2023 | 54 | 1.160 |
Why?
|
| Eye Infections, Bacterial | 3 | 2016 | 86 | 1.150 |
Why?
|
| Retinal Vasculitis | 4 | 2023 | 8 | 1.130 |
Why?
|
| Triamcinolone Acetonide | 4 | 2024 | 36 | 1.110 |
Why?
|
| Subretinal Fluid | 7 | 2024 | 11 | 1.060 |
Why?
|
| Double-Blind Method | 16 | 2025 | 1654 | 1.060 |
Why?
|
| Nerve Fibers | 3 | 2025 | 79 | 0.990 |
Why?
|
| Retinal Telangiectasis | 3 | 2025 | 5 | 0.990 |
Why?
|
| Epiretinal Membrane | 4 | 2024 | 14 | 0.960 |
Why?
|
| Adult | 52 | 2025 | 31786 | 0.940 |
Why?
|
| Peripherins | 1 | 2024 | 2 | 0.930 |
Why?
|
| Disease Progression | 15 | 2025 | 2237 | 0.920 |
Why?
|
| Fluocinolone Acetonide | 4 | 2020 | 6 | 0.880 |
Why?
|
| Vitreous Body | 5 | 2024 | 101 | 0.850 |
Why?
|
| Cataract | 3 | 2022 | 174 | 0.850 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2024 | 197 | 0.840 |
Why?
|
| Cysts | 2 | 2024 | 104 | 0.840 |
Why?
|
| Retinal Vein | 3 | 2022 | 11 | 0.820 |
Why?
|
| Ophthalmology | 6 | 2024 | 198 | 0.800 |
Why?
|
| Angiopoietin-2 | 4 | 2024 | 16 | 0.790 |
Why?
|
| Drug Delivery Systems | 3 | 2025 | 232 | 0.790 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 1153 | 0.780 |
Why?
|
| Benchmarking | 1 | 2023 | 146 | 0.780 |
Why?
|
| Eye Infections, Fungal | 4 | 2014 | 73 | 0.770 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 51 | 0.760 |
Why?
|
| Edema | 2 | 2022 | 140 | 0.730 |
Why?
|
| Carbonic Anhydrases | 11 | 2003 | 26 | 0.720 |
Why?
|
| Cataract Extraction | 3 | 2017 | 155 | 0.710 |
Why?
|
| Neovascularization, Pathologic | 7 | 2018 | 263 | 0.700 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 29 | 0.700 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 90 | 0.700 |
Why?
|
| No-Show Patients | 1 | 2020 | 3 | 0.670 |
Why?
|
| Basement Membrane | 5 | 2024 | 48 | 0.670 |
Why?
|
| Vitreoretinal Surgery | 2 | 2021 | 6 | 0.670 |
Why?
|
| Vision Disorders | 4 | 2023 | 221 | 0.670 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 33 | 0.660 |
Why?
|
| Retinal Hemorrhage | 2 | 2017 | 26 | 0.650 |
Why?
|
| Sensory Thresholds | 1 | 2019 | 38 | 0.640 |
Why?
|
| Patient Dropouts | 1 | 2019 | 52 | 0.640 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 315 | 0.630 |
Why?
|
| Postoperative Complications | 4 | 2017 | 3155 | 0.630 |
Why?
|
| Time Factors | 12 | 2025 | 6569 | 0.610 |
Why?
|
| Choroid Diseases | 1 | 2019 | 23 | 0.610 |
Why?
|
| Eye Diseases | 2 | 2011 | 130 | 0.590 |
Why?
|
| Microaneurysm | 3 | 2023 | 3 | 0.570 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 388 | 0.570 |
Why?
|
| Retinal Degeneration | 3 | 2025 | 104 | 0.550 |
Why?
|
| Lasers | 2 | 2017 | 115 | 0.530 |
Why?
|
| Patient Compliance | 1 | 2019 | 477 | 0.510 |
Why?
|
| Drug Administration Schedule | 6 | 2022 | 755 | 0.510 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 17 | 0.500 |
Why?
|
| Biomarkers | 11 | 2025 | 3424 | 0.500 |
Why?
|
| Meningoencephalitis | 1 | 2016 | 22 | 0.490 |
Why?
|
| Retinitis | 1 | 2016 | 18 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2509 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1210 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 126 | 0.470 |
Why?
|
| Silicone Oils | 2 | 2025 | 8 | 0.470 |
Why?
|
| Atrophy | 7 | 2025 | 251 | 0.460 |
Why?
|
| Vancomycin | 1 | 2017 | 235 | 0.450 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 154 | 0.450 |
Why?
|
| Cell Hypoxia | 12 | 2004 | 104 | 0.450 |
Why?
|
| Povidone-Iodine | 2 | 2011 | 10 | 0.450 |
Why?
|
| Clinical Protocols | 5 | 2022 | 245 | 0.450 |
Why?
|
| Mutation | 3 | 2025 | 6290 | 0.450 |
Why?
|
| Injections, Intraocular | 3 | 2024 | 10 | 0.440 |
Why?
|
| West Nile Fever | 1 | 2016 | 139 | 0.430 |
Why?
|
| Central Serous Chorioretinopathy | 2 | 2025 | 8 | 0.430 |
Why?
|
| Cryosurgery | 1 | 2013 | 48 | 0.420 |
Why?
|
| Fungi | 3 | 2014 | 75 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2004 | 253 | 0.410 |
Why?
|
| Precision Medicine | 2 | 2018 | 355 | 0.410 |
Why?
|
| Retinal Ganglion Cells | 2 | 2025 | 120 | 0.410 |
Why?
|
| Uveitis | 2 | 2024 | 38 | 0.400 |
Why?
|
| Choroid Neoplasms | 2 | 2013 | 25 | 0.390 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2022 | 7 | 0.380 |
Why?
|
| Transcription Factors | 10 | 2004 | 2704 | 0.380 |
Why?
|
| Nuclear Proteins | 9 | 2004 | 1334 | 0.380 |
Why?
|
| Antisepsis | 1 | 2011 | 7 | 0.380 |
Why?
|
| Mycoses | 2 | 2014 | 119 | 0.370 |
Why?
|
| Ophthalmologists | 2 | 2024 | 14 | 0.370 |
Why?
|
| Ciliary Body | 1 | 2011 | 28 | 0.360 |
Why?
|
| Bacteria | 2 | 2016 | 533 | 0.360 |
Why?
|
| Eye | 2 | 2024 | 245 | 0.360 |
Why?
|
| Young Adult | 9 | 2025 | 9852 | 0.360 |
Why?
|
| Retinal Neovascularization | 3 | 2020 | 17 | 0.360 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 273 | 0.350 |
Why?
|
| Endotamponade | 3 | 2025 | 7 | 0.350 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2004 | 388 | 0.350 |
Why?
|
| Kidney Neoplasms | 4 | 2004 | 461 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2004 | 509 | 0.350 |
Why?
|
| Retinitis Pigmentosa | 2 | 2025 | 95 | 0.350 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 60 | 0.340 |
Why?
|
| Retreatment | 4 | 2018 | 92 | 0.340 |
Why?
|
| Algorithms | 6 | 2024 | 1729 | 0.340 |
Why?
|
| Retinal Drusen | 3 | 2024 | 6 | 0.340 |
Why?
|
| Regression Analysis | 3 | 2022 | 825 | 0.340 |
Why?
|
| Aging | 1 | 2018 | 1297 | 0.340 |
Why?
|
| Surgical Flaps | 2 | 2024 | 196 | 0.340 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 1968 | 0.340 |
Why?
|
| Hospitals, University | 1 | 2010 | 105 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1068 | 0.330 |
Why?
|
| Cephalosporins | 1 | 2011 | 143 | 0.330 |
Why?
|
| Neoplasm Proteins | 10 | 2004 | 716 | 0.330 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 226 | 0.320 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 100 | 0.320 |
Why?
|
| Pharmaceutical Preparations | 3 | 2023 | 91 | 0.310 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 134 | 0.310 |
Why?
|
| Cryptococcosis | 1 | 2009 | 44 | 0.310 |
Why?
|
| Quality of Life | 4 | 2023 | 2137 | 0.310 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 7 | 0.300 |
Why?
|
| DNA-Binding Proteins | 8 | 2004 | 2161 | 0.300 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 8 | 0.300 |
Why?
|
| Capillary Permeability | 2 | 2020 | 77 | 0.300 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1193 | 0.300 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 18 | 0.300 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2008 | 17 | 0.290 |
Why?
|
| Blindness | 2 | 2021 | 76 | 0.290 |
Why?
|
| Risk Factors | 11 | 2024 | 11085 | 0.290 |
Why?
|
| Exudates and Transudates | 2 | 2021 | 22 | 0.290 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 56 | 0.290 |
Why?
|
| Adolescent | 7 | 2024 | 20505 | 0.290 |
Why?
|
| Antigens, Neoplasm | 8 | 2003 | 407 | 0.280 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 55 | 0.280 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 1306 | 0.280 |
Why?
|
| Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.280 |
Why?
|
| Single-Blind Method | 2 | 2021 | 248 | 0.270 |
Why?
|
| Teratoma | 1 | 2008 | 130 | 0.270 |
Why?
|
| Cross Infection | 1 | 2010 | 332 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1334 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2002 | 2120 | 0.250 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 97 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 3082 | 0.240 |
Why?
|
| Hexokinase | 1 | 2025 | 24 | 0.240 |
Why?
|
| Myopia | 1 | 2006 | 132 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3733 | 0.230 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 1918 | 0.230 |
Why?
|
| United States | 9 | 2024 | 11677 | 0.230 |
Why?
|
| Biomarkers, Tumor | 7 | 2008 | 1717 | 0.230 |
Why?
|
| Melanoma | 2 | 2013 | 964 | 0.230 |
Why?
|
| Intraocular Pressure | 2 | 2024 | 136 | 0.230 |
Why?
|
| Aqueous Humor | 2 | 2022 | 28 | 0.220 |
Why?
|
| Oxygen | 6 | 2018 | 577 | 0.220 |
Why?
|
| Angiopoietins | 2 | 2021 | 21 | 0.220 |
Why?
|
| Drug Approval | 1 | 2024 | 45 | 0.220 |
Why?
|
| Complement C5 | 1 | 2023 | 7 | 0.220 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 328 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 74 | 0.210 |
Why?
|
| Ligases | 2 | 2000 | 48 | 0.210 |
Why?
|
| Cyclin D1 | 1 | 2004 | 123 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 9 | 2004 | 1102 | 0.210 |
Why?
|
| Hypoxia | 4 | 2004 | 263 | 0.210 |
Why?
|
| Entropy | 1 | 2023 | 29 | 0.210 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 158 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 173 | 0.210 |
Why?
|
| Photochemotherapy | 2 | 2022 | 44 | 0.210 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.210 |
Why?
|
| Aptamers, Nucleotide | 1 | 2023 | 35 | 0.210 |
Why?
|
| Drainage | 1 | 2025 | 264 | 0.210 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 677 | 0.210 |
Why?
|
| Traction | 1 | 2022 | 9 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 104 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2013 | 264 | 0.200 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 53 | 0.190 |
Why?
|
| Prone Position | 1 | 2022 | 33 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1 | 8 | 2004 | 19 | 0.190 |
Why?
|
| Porphyrins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2023 | 243 | 0.190 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 252 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 394 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2019 | 555 | 0.180 |
Why?
|
| Equipment Design | 2 | 2020 | 604 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 377 | 0.180 |
Why?
|
| Cornea | 1 | 2006 | 594 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 341 | 0.180 |
Why?
|
| Confidence Intervals | 1 | 2021 | 300 | 0.180 |
Why?
|
| Blood-Retinal Barrier | 2 | 2020 | 3 | 0.180 |
Why?
|
| Drug Implants | 2 | 2020 | 43 | 0.180 |
Why?
|
| Computer Systems | 1 | 2021 | 38 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1733 | 0.170 |
Why?
|
| Registries | 3 | 2023 | 1568 | 0.170 |
Why?
|
| Videoconferencing | 1 | 2020 | 22 | 0.170 |
Why?
|
| Cytokines | 3 | 2022 | 1393 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 64 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 204 | 0.160 |
Why?
|
| Fractals | 1 | 2019 | 2 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 20 | 0.160 |
Why?
|
| Consensus | 1 | 2023 | 737 | 0.160 |
Why?
|
| Microcirculation | 2 | 2019 | 116 | 0.160 |
Why?
|
| Income | 1 | 2020 | 140 | 0.160 |
Why?
|
| Recurrence | 3 | 2019 | 1464 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 187 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 137 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2020 | 124 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2019 | 197 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1493 | 0.150 |
Why?
|
| Antifungal Agents | 3 | 2014 | 306 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 125 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 561 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 153 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 86 | 0.140 |
Why?
|
| Necrosis | 7 | 2004 | 221 | 0.140 |
Why?
|
| Vision, Low | 1 | 2017 | 15 | 0.140 |
Why?
|
| Visual Prosthesis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Proteins | 2 | 2000 | 1087 | 0.140 |
Why?
|
| Ultrasonography | 3 | 2024 | 997 | 0.140 |
Why?
|
| Breast Neoplasms | 5 | 2004 | 2762 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 304 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 16 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 143 | 0.130 |
Why?
|
| Beryllium | 1 | 2016 | 3 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 142 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 5175 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2002 | 225 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 13 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 471 | 0.120 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 41 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 383 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 394 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1787 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 338 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2023 | 53 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 37 | 0.110 |
Why?
|
| Fluconazole | 2 | 2014 | 50 | 0.110 |
Why?
|
| Amphotericin B | 2 | 2014 | 91 | 0.100 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2002 | 20 | 0.100 |
Why?
|
| History, 18th Century | 1 | 2013 | 70 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 765 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2020 | 792 | 0.100 |
Why?
|
| Carbonic Anhydrase IX | 8 | 2003 | 13 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 103 | 0.100 |
Why?
|
| Anterior Chamber | 1 | 2012 | 33 | 0.090 |
Why?
|
| Electroretinography | 2 | 2025 | 123 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 1189 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Telemedicine | 1 | 2018 | 500 | 0.090 |
Why?
|
| Lymphokines | 2 | 2002 | 69 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 217 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 66 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 107 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 64 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2984 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2013 | 227 | 0.090 |
Why?
|
| Glucose | 1 | 2015 | 923 | 0.090 |
Why?
|
| Florida | 1 | 2010 | 79 | 0.080 |
Why?
|
| Decision Making | 1 | 2015 | 698 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 1190 | 0.080 |
Why?
|
| Penicillins | 1 | 2011 | 155 | 0.080 |
Why?
|
| Prognosis | 7 | 2024 | 5074 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2021 | 4897 | 0.080 |
Why?
|
| Neoplasms | 2 | 2004 | 3024 | 0.080 |
Why?
|
| Child | 3 | 2024 | 25733 | 0.080 |
Why?
|
| Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 23 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2003 | 1760 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 76 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 162 | 0.080 |
Why?
|
| In Situ Hybridization | 4 | 2004 | 484 | 0.080 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2011 | 368 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2008 | 25 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 317 | 0.080 |
Why?
|
| Mesencephalon | 1 | 2008 | 38 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 667 | 0.070 |
Why?
|
| Eye Enucleation | 1 | 2008 | 50 | 0.070 |
Why?
|
| Incidence | 1 | 2016 | 3396 | 0.070 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2008 | 51 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 3025 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 376 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 364 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2003 | 1134 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 872 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3642 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2002 | 557 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 41 | 0.060 |
Why?
|
| Capillaries | 2 | 2017 | 70 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 317 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2001 | 699 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2008 | 275 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1481 | 0.060 |
Why?
|
| Transfection | 3 | 2004 | 1089 | 0.060 |
Why?
|
| Phenotype | 3 | 2025 | 4551 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3839 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 406 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2004 | 317 | 0.060 |
Why?
|
| Suspensions | 1 | 2024 | 10 | 0.060 |
Why?
|
| Search Engine | 1 | 2023 | 10 | 0.050 |
Why?
|
| Pandemics | 2 | 2023 | 1189 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 60 | 0.050 |
Why?
|
| Plasmids | 2 | 2004 | 526 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2004 | 2899 | 0.050 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 9 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2023 | 14 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2023 | 10 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 1590 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2025 | 838 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 21 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 11 | 0.050 |
Why?
|
| Indocyanine Green | 2 | 2015 | 62 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 25 | 0.050 |
Why?
|
| Syringes | 1 | 2022 | 25 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 773 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 38 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2004 | 905 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 239 | 0.050 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
| Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2021 | 9 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 343 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1313 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 39 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 2160 | 0.040 |
Why?
|
| Pedigree | 1 | 2025 | 1694 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 844 | 0.040 |
Why?
|
| RNA | 2 | 2004 | 600 | 0.040 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2001 | 43 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2000 | 51 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1070 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 132 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 28 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1349 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2001 | 89 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 57 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 91 | 0.040 |
Why?
|
| Organ Size | 1 | 2022 | 466 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 289 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 334 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2001 | 206 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 283 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 44 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1411 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 160 | 0.040 |
Why?
|
| Observation | 1 | 2020 | 45 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 110 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 830 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 584 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 65 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 429 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 394 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 218 | 0.040 |
Why?
|
| Calcinosis | 1 | 2001 | 193 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2004 | 869 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2000 | 1417 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 463 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 733 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 449 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 1832 | 0.040 |
Why?
|
| Cells | 1 | 1999 | 25 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 234 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2804 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 2651 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 746 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 82 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 697 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 37 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 691 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 91 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 293 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 508 | 0.040 |
Why?
|
| Carcinoma | 1 | 2000 | 322 | 0.040 |
Why?
|
| Caveolins | 1 | 1997 | 15 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2000 | 789 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 112 | 0.030 |
Why?
|
| European Union | 1 | 2016 | 13 | 0.030 |
Why?
|
| Infant | 2 | 2011 | 13158 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 414 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 599 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2171 | 0.030 |
Why?
|
| Gene Expression | 1 | 2001 | 1614 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 403 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 866 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 676 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 20 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 34 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 658 | 0.030 |
Why?
|
| COS Cells | 2 | 2004 | 283 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2003 | 1596 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1907 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 644 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1437 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 312 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 282 | 0.030 |
Why?
|
| Light Coagulation | 1 | 2013 | 24 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 144 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 147 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 35 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 903 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 59 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 258 | 0.020 |
Why?
|
| Hemangioma | 1 | 2013 | 97 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 2013 | 117 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2022 | 14788 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 834 | 0.020 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 103 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 397 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 165 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 72 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2001 | 104 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 826 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 867 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2651 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2009 | 78 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 103 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1603 | 0.020 |
Why?
|
| Response Elements | 2 | 1999 | 106 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1405 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 1158 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 22 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 36 | 0.010 |
Why?
|
| Immune Sera | 1 | 2004 | 95 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 35 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 60 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 400 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 121 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 19 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 336 | 0.010 |
Why?
|
| Animals | 5 | 2004 | 36377 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1928 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 33 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 26 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 31 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 543 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 231 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 43 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 128 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 714 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 717 | 0.010 |
Why?
|
| Thymidine Phosphorylase | 1 | 2001 | 13 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 1079 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 37 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 53 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 669 | 0.010 |
Why?
|
| England | 1 | 2001 | 72 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 93 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 343 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 180 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 148 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 522 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 452 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2001 | 302 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1326 | 0.010 |
Why?
|
| Mice | 3 | 2004 | 18910 | 0.010 |
Why?
|
| Cobalt | 1 | 1999 | 18 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 15 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1488 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 971 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2836 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 88 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 619 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1755 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 119 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8586 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1999 | 271 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 559 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 2210 | 0.010 |
Why?
|
| Genes, fos | 1 | 1997 | 15 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 277 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 122 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 1997 | 50 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1999 | 828 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1066 | 0.010 |
Why?
|
| Genes, ras | 1 | 1997 | 102 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 1384 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2001 | 819 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2294 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1557 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 497 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 1070 | 0.010 |
Why?
|